202 related articles for article (PubMed ID: 21145800)
1. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
Abe H; Hayes CN; Ochi H; Maekawa T; Tsuge M; Miki D; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Chayama K
J Hepatol; 2011 Jun; 54(6):1094-101. PubMed ID: 21145800
[TBL] [Abstract][Full Text] [Related]
2. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
3. Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy.
Luo S; Cassidy W; Jeffers L; Reddy KR; Bruno C; Howell CD
Clin Gastroenterol Hepatol; 2005 May; 3(5):499-506. PubMed ID: 15880320
[TBL] [Abstract][Full Text] [Related]
4. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
[TBL] [Abstract][Full Text] [Related]
5. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection.
MacQuillan GC; Mamotte C; Reed WD; Jeffrey GP; Allan JE
J Med Virol; 2003 Jun; 70(2):219-27. PubMed ID: 12696108
[TBL] [Abstract][Full Text] [Related]
7. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
[TBL] [Abstract][Full Text] [Related]
9. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
Feld JJ; Modi AA; El-Diwany R; Rotman Y; Thomas E; Ahlenstiel G; Titerence R; Koh C; Cherepanov V; Heller T; Ghany MG; Park Y; Hoofnagle JH; Liang TJ
Gastroenterology; 2011 Mar; 140(3):830-9. PubMed ID: 20854821
[TBL] [Abstract][Full Text] [Related]
10. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.
Abe H; Hayes CN; Ochi H; Tsuge M; Miki D; Hiraga N; Imamura M; Takahashi S; Kubo M; Nakamura Y; Kamatani N; Chayama K
J Med Virol; 2011 Sep; 83(9):1597-607. PubMed ID: 21739451
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
12. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.
El Awady MK; Anany MA; Esmat G; Zayed N; Tabll AA; Helmy A; El Zayady AR; Abdalla MS; Sharada HM; El Raziky M; El Akel W; Abdalla S; Bader El Din NG
J Gastroenterol Hepatol; 2011 May; 26(5):843-50. PubMed ID: 21182542
[TBL] [Abstract][Full Text] [Related]
14. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
[TBL] [Abstract][Full Text] [Related]
15. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Di Marco V; Calvaruso V; Grimaudo S; Ferraro D; Pipitone RM; Di Stefano R; Craxì A
J Viral Hepat; 2013 Feb; 20(2):113-21. PubMed ID: 23301546
[TBL] [Abstract][Full Text] [Related]
16. Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
Miyagi Y; Nomura H; Yamashita N; Tanimoto H; Ito K; Masaki N; Mizokami M; Shibuya T
J Infect Chemother; 2013 Feb; 19(1):63-9. PubMed ID: 22821355
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
19. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
20. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
